

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
BAXTER L R	PSYCHIATRY	NATL INSTITUTES OF HEALTH		BASAL GANGLIA AND 5-HT IN RITUALISTIC SOCIAL DISPLAYS	09/01/2002	08/31/2006	\$276,191.00	09/10/2003
BEAVER T M	SURGERY	N FL FOUNDATION FOR RES & EDUC		COBRA CLINICAL TRIAL	04/01/2003	03/30/2008	\$13,000.00	09/03/2003
BOBIK T A	PEDIATRICS	NATL INSTITUTES OF HEALTH		THE CONVERSION OF INACTIVE COBALAMINS TO COENZYME B12 (R01)	09/30/2003	06/30/2006	\$173,755.00	09/22/2003
BOVA F J	NEUROLOGICAL SURGERY	NATL INSTITUTES OF HEALTH		IMAGE GUIDED SURGERY USING RAPID PROTOTYPING MODELS	09/20/2003	08/31/2006	\$288,873.00	09/24/2003
BRANTLY M L	MEDICINE	ALPHA ONE FOUNDATION	S047-DEPT OF HEALTH	STATE OF FLORIDA ALPHA 1 DETECTION PROGRAM UNDER STATE OF FL CONTRACT #COHDW	07/01/2003	06/30/2004	\$200,000.00	09/08/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
BUBB M R	MEDICINE	NATIONAL SCIENCE FOUNDATION		THE CRITICAL CONCENTRATION OF ACTIN & ACTIN-BINDING PROTEIN FUNCTION	09/01/2003	08/31/2006	\$110,144.00	09/04/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
BURCHFIELD D J	PEDIATRICS	INHIBITEX		A MULTI-CTR PHASE II STDY TO ASSESS THE SAF & PRELIMINARY EF FICY OF MULTIPLE DOSES OF INH-A21, A DONOR-SELECTED	09/13/2002	08/19/2004	\$2,000.00	09/19/2003
CLANCY C J	MOLECULAR GENETICS & MICROBIO	NATL INSTITUTES OF HEALTH		ORAL AND VAGINAL GENE EXPRESION BY CANDIDA DURING AIDS	09/10/2003	05/31/2005	\$217,500.00	09/16/2003
DONNELLY JR W H	PATHOLOGY & LABORATORY MED	THOMAS H MAREN FOUNDATION		THE ANATOMIC PATHOLOGY DATABASE	05/01/2003	11/28/2005	\$7,000.00	09/10/2003
DUNN B M	BIOCHEMISTRY & MOLECULAR BIO	NATIONAL SCIENCE FOUNDATION		COLLABORATIVE RESEARCH: A FUNCTIONAL GENOMICS APPROACH TO N-TERMINAL MODIFYING ENZYMES	10/01/2003	09/30/2006	\$155,195.00	09/23/2003
GUTHRIE T H	UFHSCJ/MEDICINE	CELGENE CORPORATION		A PHASE II TRILA OF INTERLEUKIN-2 PLUS THALIDOMIDE WITH LOCALLY ADVANCED METASTIC MELANOMA &	07/16/2003	06/30/2005	\$2,500.00	09/29/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
ICZKOWSKI K A	PATHOLOGY & LABORATORY MED	SOUTHWEST ONCOLOGY GROUP	F027-NIH	SWOG 9217 - CHEMOPREVENTION OF PROSTATE CANCER WITH FINASTERIDE (PROSCAR), PHASE III, INTERGROUP	07/14/2003	05/31/2004	\$288.00	09/04/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
JANTZ M A	MEDICINE	ELI LILLY & COMPANY		EFFICACY AND SAFETY OF DROTRECIGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH EARLY STAGE SEVERE SEPSIS	08/12/2002	08/28/2004	\$2,125.00	09/24/2003
JOHNSON R J	MEDICINE	NATL INSTITUTES OF HEALTH		ENDOTHELIAL CELL IN PROGRESSIVE RENAL DISEASE	09/01/2003	05/31/2005	\$346,550.00	09/30/2003
KLODELL C T	SURGERY	BIOMARIN PHARMACEUTICAL		BIOMARIN STUDY PROTOCOL NTL 06: A PHASE III COMPARISON OF NEUTRALASE TO PROTAMINE IN PATIENTS UNDERGOING PRIMARY	04/17/2003	04/15/2004	\$7,000.00	09/02/2003
MOYER R W	MOLECULAR GENETICS & MICROBIO	VAXGEN		DETERMINATION OF EFFICACY OF THE SMALLPOX VACCINE LC16M8 IN THE RABBIT POX-RABBIT MODEL	10/01/2003	09/30/2004	\$108,222.00	09/29/2003
PIGOTT T A	PSYCHIATRY	FOREST LABORATORIES INC		AN OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY OF NERAMEZANE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER	12/18/2002	12/31/2004	\$7,200.00	09/02/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
RAGAN P D	MEDICINE	GULF COAST NORTH AREA HLTH EDU		IMPROVE ACCESS TO QUALITY HEALTH CARE IN THE RURAL AND UNDERSERVED AREAS OF THE GSAHEC'S 4 COUNTY SERVICE	09/11/2003	06/30/2004	\$15,000.00	09/24/2003
RATHORE M H	UFHSCJ/PEDIATRICS	GLAXO SMITHKLINE		AN OPN-LBL SINGLE-DOSE MUTLI-CTR PHARMACOKINETIC SAFETY & TO LERABILITY STUDY OF VALACICLOVIR ORAL	07/18/2003	07/17/2004	\$1,488.00	09/18/2003
RATHORE M H	UFHSCJ/PEDIATRICS	GLAXO SMITHKLINE		AN OPN-LBL, SINGLE-DOSE, MULT-CTR, PHARMACOKINETIC SAFETY & TOLERABILITY STUDY OF VALACICLOVIR ORAL	07/18/2003	07/17/2004	\$1,450.00	09/23/2003
RATHORE M H	UFHSCJ/PEDIATRICS	GLAXO SMITHKLINE		AN OPN-LBL SINGAL-DOSE MUTI-CTR PHARMACOKINETIC SAFETY & TOL ERABILITY STUDY OF VALACICLOVIR ORAL	07/18/2003	07/17/2004	\$1,513.00	09/23/2003
RIGGS CHARLES J	CANCER CENTER	FUJISAWA HEALTHCARE INC		AN EXPLORATORY PHASE II, MULTI-CTR OPEN-LABEL TRIAL EVAUATIN G THE ACTIVITY AND TOLERABILITY OF FK228 IN	06/05/2003	06/09/2004	\$22,800.00	09/10/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
SCHATZ D A	PEDIATRICS	ELI LILLY & COMPANY		THE GLOBAL HYPOPITUITARY CONTROL AND COMPLICATIONS STUDY (HYPOCCS): ID #B9R-MC-GDGA	10/21/2002	09/29/2004	\$3,828.00	09/16/2003